Treatments & Interventions
Dextran 70
substance
Propylene glycol
substance
Carboxymethylcellulose sodium
substance
Vitamin A
substance
Propylene glycol diacetate
substance
Cod liver oil
substance
Hydroxypropyl cellulose
substance
Hydroxyethylcellose
substance
Sodium chloride
substance
Hypromellose
substance
Carboxymethylcellulose
substance
Retinol acetate
substance
Vitamin A palmitate
substance
Macrogol 300
substance
Macrogol 400
substance
Lifitegrast
substance
Perfluorohexyloctane
substance
Clinical Trials
Recent Trials
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
Assessment of CataClear, Tear Film Stability, Tear Volume, and Dry Eye Symptoms Using Stem Cells Fortified Eye Drops
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery
Optimizing the Ocular Surface With Systane COMPLETE Pre- and Post-operatively in Patients With Dry Eye Planning for Cataract Surgery: An Extension Study of Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery
Research Evidence
Peer-reviewed studies linked via MeSH term "Xerophthalmias" from the MEDLINE/PubMed database.
Research data from MEDLINE/PubMed
Quick Facts
- SNOMED CT
- 46152009
- UMLS CUI
- C0043349
- Fully Specified Name
- Tear film insufficiency (disorder)
- Specialists
- 0
- Diagnostic Biomarkers
- 0
- Known Treatments
- 17
- Clinical Trials
- 147
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.